Cartesian Therapeutics (RNAC) Retained Earnings (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Retained Earnings for 12 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings changed 0.13% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$4.6 million (changed 0.13% YoY), while the FY2025 annual figure was $700.7 million, up 1.57% from the prior year.
• Retained Earnings retreated to -$4.6 million in Q1 2026 per RNAC's latest filing, from $700.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $700.7 million in Q4 2025 and bottomed at -$729.8 million in Q3 2025.
• Historically, Retained Earnings has averaged $65.6 million across 5 years, with a median of -$4.6 million in 2026.
• On a YoY basis, Retained Earnings climbed as much as 15097.54% in 2024 and fell as far as 14670.75% in 2024.
• Cartesian Therapeutics' Retained Earnings stood at $493.3 million in 2022, then sank by 100.93% to -$4.6 million in 2023, then surged by 15097.54% to $689.9 million in 2024, then rose by 1.57% to $700.7 million in 2025, then sank by 100.65% to -$4.6 million in 2026.
• Business Quant data shows RNAC's Retained Earnings at -$4.6 million in Q1 2026, $700.7 million in Q4 2025, and -$729.8 million in Q3 2025.